SCHOLAR ROCK HOLDING CORPORATION Stock or Unit Option Plan Expense
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Stock or Unit Option Plan Expense of $100.00 thousand for the 3-month period ending 2022-06-30, per its 10-K filed 2024-03-19.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2024-03-19
- SCHOLAR ROCK HOLDING CORPORATION stock or unit option plan expense for the quarter ending 2022-06-30 was $100.00K.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month |
|---|---|---|
| 2022-06-30 | $100.00K 10-K · filed 2024-03-19 | $100.00K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |